Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Standardized grass pollen extract transition period is possible, FDA indicates.

Executive Summary

STANDARDIZED GRASS POLLEN EXTRACT TRANSITION PERIOD COULD BE ALLOWED by FDA, the agency has indicated. In April 1994, FDA informed allergenic product manufacturers that eight varieties of grass pollen extracts must be standardized to bioequivalent allergy units. The deadline for changeover was initially April 1996; it was subsequently extended to July 1997, but to date only two manufacturers have received approvals.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel